Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Josh Levitsky, MD"'
Autor:
Claire Harrington, MD, Megan Kosirog, MD, Patrick Campbell, MD, Dyanna Gregory, MS, Amna Daud, MD, MPH, Josh Levitsky, MD, Jane L. Holl, MD, MPH, Donald M. Lloyd-Jones, MD, ScM, Lisa B. VanWagner, MD, MSc
Publikováno v:
Transplantation Direct, Vol 8, Iss 2, p e1288 (2022)
Background. Tobacco use is a modifiable risk factor for cardiovascular events (CVEs) in liver transplant recipients (LTRs), but there is a paucity of data about practitioner adherence to tobacco cessation guidelines for LTRs. We sought to assess adhe
Externí odkaz:
https://doaj.org/article/26496cbae15041668f6bfbec496de7c3
Autor:
Christopher J. Mowry, MD, Cristina Alonso, PhD, Marta Iruarrizaga-Lejarreta, PhD, Pablo Ortiz, MD, PhD, Josh Levitsky, MD, MS, Mary Rinella, MD
Publikováno v:
Transplantation Direct, Vol 7, Iss 12, p e784 (2021)
Background. Nonalcoholic fatty liver disease (NAFLD) is a rising indication for liver transplantation (LT). Identification of NAFLD recurrence and those at risk for more progressive disease after LT remains elusive as the diagnosis requires biopsy, w
Externí odkaz:
https://doaj.org/article/7d381d77ca3448e398a9f05fef8fee10
Autor:
Patrick T. Campbell, MD, Megan Kosirog, MD, Blessing Aghaulor, MD, Dyanna Gregory, MS, Stewart Pine, MD, Amna Daud, MBBS, MPH, Arighno Das, MD, Daniel J. Finn, MPH, Josh Levitsky, MD, Jane L. Holl, MD, MPH, Donald M. Lloyd-Jones, MD, ScM, Lisa B. VanWagner, MD
Publikováno v:
Transplantation Direct, Vol 7, Iss 10, p e766 (2021)
Background. Chronic kidney disease (CKD) is associated with cardiovascular (CV) events, a leading complication in liver transplant recipients (LTRs). Timely subspecialty care is associated with improved clinical outcomes in patients with CKD. This st
Externí odkaz:
https://doaj.org/article/d034f99615c54215b4a2b8e7a70aaae8
Autor:
Osvald Nitski, BASc, Amirhossein Azhie, MD, Fakhar Ali Qazi-Arisar, MD, Xueqi Wang, BSc, Shihao Ma, BASc, Leslie Lilly, MD, Kymberly D Watt, MD, Josh Levitsky, MD, Sumeet K Asrani, MD, Douglas S Lee, MD, Barry B Rubin, MD, Mamatha Bhat, MD, Bo Wang, PhD
Publikováno v:
The Lancet: Digital Health, Vol 3, Iss 5, Pp e295-e305 (2021)
Summary: Background: Survival of liver transplant recipients beyond 1 year since transplantation is compromised by an increased risk of cancer, cardiovascular events, infection, and graft failure. Few clinical tools are available to identify patients
Externí odkaz:
https://doaj.org/article/a1876e9ca7624f29b1eed80837f0e8a0
Autor:
Imran Nizamuddin, MD, Themistoklis Kourkoumpetis, MD, MPH, Cecil G. Wood, MD, Josh Levitsky, MD, MS
Publikováno v:
Transplantation Direct, Vol 7, Iss 5, p e694 (2021)
Posttransplant lymphoproliferative disorder (PTLD) in liver transplant recipients is relatively uncommon, with an estimated incidence of 1%–3%. Retrospective reviews of liver transplant recipients have mainly reported posttransplant lymphoprolifera
Externí odkaz:
https://doaj.org/article/fcf10d8ada194302a2d43ae3e604fd81
Autor:
Josh Levitsky, MD, Ajay Singhvi, MD, H. Steven Sadowsky, MS, Ayelet Cohen, BA, Alysen Demzik, BA, Lisa VanWagner, MD, MSC, Mary Rinella, MD
Publikováno v:
Transplantation Direct, Vol 3, Iss 8, p e188 (2017)
Background. Nonalcoholic steatohepatitis (NASH) is a leading indication for liver transplantation (LT). We hypothesized that weight gain after LT may be exacerbated by reduced metabolic rates due to the LT procedure, particularly during exercise. We
Externí odkaz:
https://doaj.org/article/ea18c06358844236a485831c02a5599d